The Effect of Acute Normovolemic Hemodilution in Bone Tumor Surgery
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
About this trial
The prevention of intraoperative allogenetic blood transfusion has the potential to reduce complications, hospital stays, and long-term prognosis in patients undergoing bone cancer surgery. Data from previous studies suggest that the clinical efficacy of acute normovolemic hemodilution (ANH) has always been controversial. The HEAL trial will assess whether ANH will reduce the volume of intraoperative allogeneic red blood cell transfusion in patients undergoing bone cancer surgery.
Eligibility criteria
Qualifiers
age 18 to 75 years;
undergoing elective bone tumor resection surgery;
preoperative hemoglobin ≥11 g/dL;
Disqualifiers
using a tourniquet;
palliative operation or minimally invasive surgery;
BMI<18.5 or >30Kg/m²;
international normalized ratio (INR) >1.5 or platelet count <100 × 10^9/L;
Trial design
Treatments tested in this trial
- acute normovolemic hemodilution
Treatment groups
150 Participants
are divided into 2 treatment groupsLocations
1The Second Affiliated Hospital of Zhejiang University anesthesiology department310000, HangzhouZhejiang, China
Sponsors and collaborators
Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead sponsor
Source ClinicalTrials.gov